Effect of Salvianolic Acid B-loaded Mesoporous Silica Nanoparticles on Myocardial Ischemia-Reperfusion Injury

Ming-Juan Yang,Xiao-Ying Han,Ou Qiao,Hai-Xia Ji,Yi Zhang,Xin-Yu Zhang,Wen-Zhe Wang,Xia Li,Juan Wang,Lan-Ping Guo,Lu-Qi Huang,Wen-Yuan Gao
DOI: https://doi.org/10.53388/tmr20230117001
2023-01-01
Traditional Medicine Research
Abstract:Background: Currently, no drugs can specifically improve clinical cardiac ischemia-reperfusion injury or the prognosis of hemodialysis. Salvianolic acid B (SalB) is a widely used cardiac protectant; however, its clinical application is limited by its low oral bioavailability and poor intestinal absorption. The exploration of its preparation and clinical applications has become a research hotspot in recent years. Methods: To determine whether mesoporous silica nanoparticles (MSNs) efficiently delivered SalB to the heart and SalB@MSNs-RhB reduced myocardial ischemia-reperfusion injury, we constructed a myocardial ischemia-reperfusion male rat model, hypoxia/reoxygenation cardiomyocytes, and treated them with SalB@MSNs-RhB. Results: SalB@MSNs-RhB showed improved bioavailability, therapeutic effect, heightened JAK2/STAT3-dependent pro-survival signaling, and antioxidant responses, thereby protecting cardiomyocytes from ischemia-reperfusion injury-induced oxidative stress and apoptosis. Conclusion: This use of SalB-loaded nanoparticles and investigation of their mechanism of action may provide a new strategy for treating cardiomyocytes. Thus, hypoxia/reoxygenation promotes the clinical application of SalB.
What problem does this paper attempt to address?